Products
Ucenprubart Biosimilar Monoclonal Antibody (CD200R1) for Research
Cat No.: GMP-Bios-INN-1436
Anti-MOX2R/CD200R1 therapeutic antibody (Pre-made Ucenprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ucenprubart (development code LY3454738) is a humanized monoclonal antibody targeting CD200R1. It is developed by Eli Lilly and Company for Atopic dermatitis, Chronic urticaria, Immunological disorders in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1436-1mg | 1mg | 3090 |
| GMP-Bios-INN-1436-10mg | 10mg | |
| GMP-Bios-INN-1436-100mg | 100mg | |
| GMP-Bios-INN-1436-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ucenprubart biosimilar, Whole mAb, Anti-MOX2R/CD200R1 Antibody: Anti-CD200R1/Cell surface glycoprotein CD200 receptor 1/CD200 cell surface glycoprotein receptor/Cell surface glycoprotein OX2 receptor 1 therapeutic antibody |
| INN Name | Ucenprubart |
| Target | MOX2R/CD200R1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Eli Lilly and Company |
| Conditions Approved | na |
| Conditions Active | Atopic dermatitis;Chronic urticaria;Immunological disorders |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
